Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Gastric Cancer Therapy Market Expected To Grow In Terms Of Size?

In the past few years, there has been a significant increase in the size of the gastric cancer therapy market. The market value is projected to increase from $4.12 billion in 2024 to $4.50 billion in 2025, with a compound annual growth rate (CAGR) of 9.3%. The historic growth observed can be accredited to factors such as the growing incidence of h. pylori infection, heightened intake of tobacco and alcohol, an increasing number of the elderly, a scarcity of early diagnostic tools, and the rising popularity of chemotherapy treatments.

Strong expansion is anticipated for the gastric cancer therapy market with predictions of its size reaching $6.39 billion by 2029, which is tantamount to a compound annual growth rate (CAGR) of 9.1%. The accelerated market growth in the projected timeline is tied to various factors such as the upsurge in biomarker-oriented therapies, the inclination towards combined treatment strategies, heightened investments in the field of oncology research and development, proliferation of healthcare infrastructures in burgeoning economies, and the acceptance of liquid biopsies for surveillance purposes. The predicted period will also witness emerging trends such as the progression of individualized medicine, emphasis on precision drug delivery systems, escalation in clinical trials of newly discovered antibodies, AI incorporation in diagnostic imaging and the advancement of amalgamated therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25767&type=smp

What Are The Primary Factors Supporting The Gastric Cancer Therapy Market Expansion?

The growth of the gastric cancer therapy market is anticipated to gain momentum due to the increasing occurrence of helicobacter pylori infection. This type of bacterial infection, which mainly impacts the lining of the stomach, is a key contributor to chronic gastritis and gastric cancer. The upsurge in helicobacter pylori infection instances can largely be attributed to unsatisfactory sanitation practices as inadequate hygiene and polluted food or water enable easy transmission of the bacteria via oral or fecal routes. Gastric cancer therapies aim to diminish the risk of gastric cancer triggered by helicobacter pylori infection by administering treatment for the infection, reducing related gastric inflammation and cellular damage, and impeding the advancement of chronic gastritis and atrophic changes that could result in the malignant transformation of the gastric mucosa. For instance, a report by the Government of Canada in November 2024 states that as of January 2023, helicobacter pylori infection recurrence rates could be as high as 19%, although this rate may differ based on geographical location and age. Consequently, the burgeoning incidence of helicobacter pylori infection is fueling the gastric cancer therapy market’s expansion.

Which Segmentation Categories Are Highlighted In The Gastric Cancer Therapy Market Analysis?

The gastric cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents

3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous

4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage

5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings

Subsegments:

1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy

2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy

5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy

Which Market Trends Are Expected To Define The Future Of The Gastric Cancer Therapy Market?

Leading firms in the gastric cancer therapy market are concentrating their efforts on the creation of novel treatments like combination therapy, with the aim of enhancing treatment potency and patient well-being. This kind of therapy combines two or more treatments, such as chemotherapy, specific therapies, or immunotherapy, to increase total effectiveness. One example of this was in December 2024, when BeOne Medicines Ltd., formerly known as BeiGene and situated in China, was granted approval from the U.S. Food and Drug Administration (FDA) to use Tevimbra (tislelizumab-jsgr) in conjunction with platinum-based and fluoropyrimidine-based chemotherapy to treat adults suffering from inoperable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with tumors that display PD-L1 (=1). The approval was contingent on results from the Phase 3 RATIONALE-305 trial, which showed that the median overall survival was considerably improved to 15.0 months when using combination therapy, compared to 12.9 months with chemotherapy alone, which translates to a 20% decrease in mortality risk. This significant development underscores proliferating trend among top pharmaceutical companies towards investing in innovative, multi-pronged treatment approaches that incorporate immunotherapy along with traditional chemotherapy protocols to boost clinical results, put off disease advancement, and heighten survival chances in patients with severe gastric cancer.

Which Organizations Are At The Forefront Of The Gastric Cancer Therapy Market?

Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc., Imugene Limited, LintonPharm Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Gastric Cancer Therapy Market?

North America was the largest region in the gastric cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25767&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Therapy Market 2025, By The Business Research Company

Gastroparesis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastric Volvulus Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

Gastric Ulcers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-ulcers-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model